NCT04148937 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 17
- group Id
- BG008
- value
- 52
- units
- Participants
- groups
- description
- Participants received 150 milligrams (mg) LY3475070 orally once daily (QD) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
- id
- BG000
- title
- Cohort A - 150mg QD LY3475070
- description
- Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
- id
- BG001
- title
- Cohort A - 300mg QD LY3475070
- description
- Participants received 300mg LY3475070 orally twice daily (BID) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
- id
- BG002
- title
- Cohort A - 300mg BID LY3475070
- description
- Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
- id
- BG003
- title
- Cohort A - 600mg QD LY3475070
- description
- Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
- id
- BG004
- title
- Cohort B - 150mg QD LY3475070 + Pembrolizumab
- description
- Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
- id
- BG005
- title
- Cohort B - 150mg BID LY3475070 + Pembrolizumab
- description
- Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
- id
- BG006
- title
- Cohort B - 300mg QD LY3475070 + Pembrolizumab
- description
- Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study
- id
- BG007
- title
- Cohort B - 300mg BID LY3475070 + Pembrolizumab
- description
- Total of all reporting groups
- id
- BG008
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.57
- value
- 66.50
- group Id
- BG001
- spread
- 13.04
- value
- 65.83
- group Id
- BG002
- spread
- 12.22
- value
- 66.83
- group Id
- BG003
- spread
- 13.02
- value
- 66.25
- group Id
- BG004
- spread
- 7.23
- value
- 63.67
- group Id
- BG005
- spread
- 11.65
- value
- 59.73
- group Id
- BG006
- spread
- 0
- value
- 61
- group Id
- BG007
- spread
- 7.66
- value
- 66
- group Id
- BG008
- spread
- 10.05
- value
- 64.58
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 17
- title
- Female
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 15
- group Id
- BG008
- value
- 35
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 3
- group Id
- BG008
- value
- 3
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 14
- group Id
- BG008
- value
- 49
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 13
- group Id
- BG008
- value
- 38
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 4
- group Id
- BG008
- value
- 14
- title
- United Kingdom
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- population Description
- All enrolled participants.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 17
- group Id
- BG008
- value
- 52
- units
- Participants
- groups
- description
- Participants received 150 milligrams (mg) LY3475070 orally once daily (QD) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
- id
- BG000
- title
- Cohort A - 150mg QD LY3475070
- description
- Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
- id
- BG001
- title
- Cohort A - 300mg QD LY3475070
- description
- Participants received 300mg LY3475070 orally twice daily (BID) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
- id
- BG002
- title
- Cohort A - 300mg BID LY3475070
- description
- Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
- id
- BG003
- title
- Cohort A - 600mg QD LY3475070
- description
- Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
- id
- BG004
- title
- Cohort B - 150mg QD LY3475070 + Pembrolizumab
- description
- Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
- id
- BG005
- title
- Cohort B - 150mg BID LY3475070 + Pembrolizumab
- description
- Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
- id
- BG006
- title
- Cohort B - 300mg QD LY3475070 + Pembrolizumab
- description
- Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study
- id
- BG007
- title
- Cohort B - 300mg BID LY3475070 + Pembrolizumab
- description
- Total of all reporting groups
- id
- BG008
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.57
- value
- 66.50
- group Id
- BG001
- spread
- 13.04
- value
- 65.83
- group Id
- BG002
- spread
- 12.22
- value
- 66.83
- group Id
- BG003
- spread
- 13.02
- value
- 66.25
- group Id
- BG004
- spread
- 7.23
- value
- 63.67
- group Id
- BG005
- spread
- 11.65
- value
- 59.73
- group Id
- BG006
- spread
- 0
- value
- 61
- group Id
- BG007
- spread
- 7.66
- value
- 66
- group Id
- BG008
- spread
- 10.05
- value
- 64.58
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 17
- title
- Female
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 15
- group Id
- BG008
- value
- 35
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 3
- group Id
- BG008
- value
- 3
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 14
- group Id
- BG008
- value
- 49
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 13
- group Id
- BG008
- value
- 38
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 4
- group Id
- BG008
- value
- 14
- title
- United Kingdom
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- population Description
- All enrolled participants.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle